Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Lexaria Bioscience Corp (LXX.CN)

Lexaria Bioscience Corp (LXX.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Lexaria Bioscience Corp. (NASDAQ: LEXX) Emerging as Leader in Pursuit of More-Effective Hypertension Treatment Globe NewsWire - Thu Sep 16, 2021

NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Hypertension: The Silent Killer Making...

LXRP : 0.2249 (-10.68%)
LXX.CN : 8.400 (-1.18%)
LEXX : 2.09 (+3.98%)
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Throw Hat into Hypertension Ring with Proprietary Drug-Delivery System Globe NewsWire - Wed Sep 15, 2021

NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"),...

LXRP : 0.2249 (-10.68%)
LXX.CN : 8.400 (-1.18%)
LEXX : 2.09 (+3.98%)
Lexaria Bioscience Corp. (NASDAQ: LEXX) on Forefront of Exciting Hypertension Innovation Globe NewsWire - Fri Aug 6, 2021

NEW YORK, Aug. 06, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Cardiovascular Disease Drug Market Offers...

LXRP : 0.2249 (-10.68%)
LXX.CN : 8.400 (-1.18%)
LEXX : 2.09 (+3.98%)
Lexaria Bioscience Corp. (NASDAQ: LEXX) Leads the Way in Innovating Hypertension Treatment Globe NewsWire - Wed Aug 4, 2021

NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"),...

LXRP : 0.2249 (-10.68%)
LXX.CN : 8.400 (-1.18%)
LEXX : 2.09 (+3.98%)
Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets AccessWire - Mon Jul 5, 2021

KELOWNA, BC / ACCESSWIRE / July 5, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that...

LEXX : 2.09 (+3.98%)
LEXXW : 0.6145 (+0.74%)
LXX.CN : 8.400 (-1.18%)
Lexaria Announces 2021 Annual Meeting Results AccessWire - Tue Jun 29, 2021

KELOWNA, BC / ACCESSWIRE / June 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results...

LEXX : 2.09 (+3.98%)
LEXXW : 0.6145 (+0.74%)
LXX.CN : 8.400 (-1.18%)
Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs AccessWire - Tue Jun 15, 2021

DehydraTECH™ improves delivery into bloodstream of orally administered remdesivir and ebastine in study VIRAL-A20-2 KELOWNA, BC / ACCESSWIRE / June 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW)...

LEXX : 2.09 (+3.98%)
LEXXW : 0.6145 (+0.74%)
LXX.CN : 8.400 (-1.18%)
Lexaria Provides Progress Report on Six R&D Programs AccessWire - Wed Jun 9, 2021

- All studies are using DehydraTECH™ 2.0 formulations for multiple market applications, including antivirals, hypertension, NSAIDs and oral nicotine - These studies are part of Lexaria's 2021 applied...

LEXX : 2.09 (+3.98%)
LEXXW : 0.6145 (+0.74%)
LXX.CN : 8.400 (-1.18%)
Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1 AccessWire - Mon Jun 7, 2021

- Dosing Is Complete in First of Three Human Clinical Studies Hoped To Validate Lexaria’s Patented Technology for Hypertension Relief - Study Tested an Advanced “DehydraTECH™ 2.0” CBD Formulation...

LEXX : 2.09 (+3.98%)
LEXXW : 0.6145 (+0.74%)
LXX.CN : 8.400 (-1.18%)
Lexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus AccessWire - Thu Jun 3, 2021

KELOWNA, BC / ACCESSWIRE / June 3, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that remdesivir...

LEXX : 2.09 (+3.98%)
LEXXW : 0.6145 (+0.74%)
LXX.CN : 8.400 (-1.18%)

Barchart Exclusives

Is It Time to Buy This Dividend Stock With Nuclear Energy Upside? Barchart - Mon Nov 18, 6:30PM CST
Apart from its prowess in nuclear energy, this energy company is also deploying AI. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot